Reports Q3 revenue $83.3M, consensus $80.77M. “In my initial weeks as CEO, I am pleased to report we delivered a strong performance. We accelerated U.S. system placements, demonstrating strong demand for the HYDROS(R) Robotic System, and achieved 43% year over year global revenue growth,” said Larry Wood, chief executive officer. “This quarter’s results underscore the strength of our business and the growing adoption of Aquablation therapy. My first two months at PROCEPT have only deepened my confidence in our significant growth potential. We remain focused on expanding awareness of Aquablation(R) therapy, driving patient activation and advancing our mission.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- PRCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Procept Biorobotics’ WATER IV Study: A Game Changer in Prostate Cancer Treatment?
- Procept Biorobotics’ Aquablation Therapy Study: A Potential Game-Changer for Prostate Treatment
- Buy Rating Affirmed Amid Potential Upside and Strategic Leadership Changes
- Procept BioRobotics price target lowered to $50 from $64 at Truist